Company Overview of OPKO Biologics
OPKO Biologics, a development stage biopharmaceutical company, is engaged in the development of proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide (CTP) is used to develop new and proprietary versions of existing therapeutic proteins that have longer life spans than therapeutic proteins without CTP. The company’s products under development include human growth hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; and factor IX that is offered to Hemophilia B patients to control blood clotting or coagulation. Its products under development als...
7 Golda Meir Street
Weizmann Science Park
Key Executives for OPKO Biologics
Chief Executive Officer and Director
President, Director and Member of Governance Committee
Chief Financial Officer and Principal Accounting Officer
Chief Operating Officer of Prolor Biotech Ltd
Director and Chief Scientific Officer of Prolor Biotech Ltd
Compensation as of Fiscal Year 2015.
OPKO Biologics Key Developments
PROLOR Biotech, Inc.(TASE:PBTH) dropped from TA-100 Index
Sep 2 13
PROLOR Biotech, Inc. will be removed from TA-100 Index.
PROLOR Biotech, Inc., Special/Extraordinary Shareholders Meeting, Aug 28, 2013
Jul 29 13
PROLOR Biotech, Inc., Special/Extraordinary Shareholders Meeting, Aug 28, 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries